InnoCan Pharma Corporation (INNPF)
OTCMKTS · Delayed Price · Currency is USD
0.1400
+0.0200 (16.67%)
Apr 23, 2025, 4:00 PM EDT

InnoCan Pharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Apr '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Market Capitalization
3642634015749
Upgrade
Market Cap Growth
-32.69%-32.69%58.58%-74.75%220.33%176.32%
Upgrade
Enterprise Value
3339593315147
Upgrade
Last Close Price
0.140.160.300.210.640.25
Upgrade
PS Ratio
1.221.444.6115.50801.466129.83
Upgrade
PB Ratio
5.106.0314.346.3717.43-13.59
Upgrade
P/TBV Ratio
6.938.2015.336.2017.35-
Upgrade
EV/Sales Ratio
1.071.334.3212.89771.515897.57
Upgrade
Debt / Equity Ratio
0.000.000.010.010-0.01
Upgrade
Asset Turnover
3.633.631.960.260.020.00
Upgrade
Inventory Turnover
1.281.281.170.550.16-
Upgrade
Quick Ratio
2.482.481.797.103.150.44
Upgrade
Current Ratio
4.094.092.689.413.510.54
Upgrade
Return on Equity (ROE)
-4.59%-4.59%-80.07%-51.05%-373.46%-
Upgrade
Return on Assets (ROA)
-9.62%-9.62%-34.16%-40.06%-55.30%-85.40%
Upgrade
Return on Capital (ROIC)
-13.61%-13.61%-44.52%-51.29%-171.78%-
Upgrade
Earnings Yield
-5.12%-4.33%-7.47%-9.49%-6.40%-20.30%
Upgrade
FCF Yield
-4.45%-3.77%-6.28%-15.36%-4.25%-7.52%
Upgrade
Buyback Yield / Dilution
-8.96%-8.96%-3.23%-10.87%-38.59%-34.30%
Upgrade
Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.